A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH). The gut-liver axis is considered to be strongly implicated in the pathogenesis of MASLD. We aimed to characterize the gut microbiota co...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1297378/full |
| _version_ | 1797391350981722112 |
|---|---|
| author | Javier Martínez-Sanz Javier Martínez-Sanz Alba Talavera-Rodríguez Alba Talavera-Rodríguez Alba Talavera-Rodríguez Jorge Díaz-Álvarez Marta Rosas Cancio-Suárez Marta Rosas Cancio-Suárez Juan Miguel Rodríguez Claudio Alba María Luisa Montes Rosa Martín-Mateos Diego Burgos-Santamaría Santiago Moreno Santiago Moreno Sergio Serrano-Villar Sergio Serrano-Villar Matilde Sánchez-Conde Matilde Sánchez-Conde |
| author_facet | Javier Martínez-Sanz Javier Martínez-Sanz Alba Talavera-Rodríguez Alba Talavera-Rodríguez Alba Talavera-Rodríguez Jorge Díaz-Álvarez Marta Rosas Cancio-Suárez Marta Rosas Cancio-Suárez Juan Miguel Rodríguez Claudio Alba María Luisa Montes Rosa Martín-Mateos Diego Burgos-Santamaría Santiago Moreno Santiago Moreno Sergio Serrano-Villar Sergio Serrano-Villar Matilde Sánchez-Conde Matilde Sánchez-Conde |
| author_sort | Javier Martínez-Sanz |
| collection | DOAJ |
| description | IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH). The gut-liver axis is considered to be strongly implicated in the pathogenesis of MASLD. We aimed to characterize the gut microbiota composition in PLWH and MASLD and compare it with that of two control groups: PLWH without MASLD and individuals with MASLD without HIV infection.MethodsWe collected clinical data and stool samples from participants. Bacterial 16S rRNA genes were amplified, sequenced, and clustered into operational taxonomic unit. Alpha diversity was studied by Shannon and Simpson indexes. To study how different the gut microbiota composition is between the different groups, beta diversity estimation was evaluated by principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity. To further analyze differences in microbiome composition we performed a linear discriminant analysis (LDA) effect size (LEfSe).ResultsWe included 30 HIV+MASLD+, 30 HIV+MASLD- and 20 HIV-MASLD+ participants. Major butyrate producers, including Faecalibacterium, Ruminococcus, and Lachnospira dominated the microbiota in all three groups. Shannon’s and Simpson’s diversity metrics were higher among MASLD+ individuals (Kruskal-Wallis p = 0.047). Beta diversity analysis showed distinct clustering in MASLD-, with MASLD+ participants overlapping regardless of HIV status (ADONIS significance <0.001). MASLD was associated with increased homogeneity across individuals, in contrast to that observed in the HIV+NAFDL- group, in which the dispersion was higher (Permanova test, p value <0.001; ANOSIM, p value <0.001). MASLD but not HIV determined a different microbiota structure (HIV+MASLD- vs. HIV+MASLD+, q-value = 0.002; HIV-MASLD+ vs. HIV+MASLD+, q-value = 0.930; and HIV-MASLD+ vs. HIV+MASLD-, q-value < 0.001). The most abundant genera in MASLD- were Prevotella, Bacteroides, Dialister, Acidaminococcos, Alloprevotella, and Catenibacterium. In contrast, the most enriched genera in MASLD+ were Ruminococcus, Streptococcus, Holdemanella, Blautia, and Lactobacillus.ConclusionsWe found a microbiome signature linked to MASLD, which had a greater influence on the overall structure of the gut microbiota than HIV status alone. |
| first_indexed | 2024-03-08T23:31:43Z |
| format | Article |
| id | doaj.art-601912c75d3b41ac9eda5f269c5bf3d0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T23:31:43Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-601912c75d3b41ac9eda5f269c5bf3d02023-12-14T12:45:52ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.12973781297378A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver diseaseJavier Martínez-Sanz0Javier Martínez-Sanz1Alba Talavera-Rodríguez2Alba Talavera-Rodríguez3Alba Talavera-Rodríguez4Jorge Díaz-Álvarez5Marta Rosas Cancio-Suárez6Marta Rosas Cancio-Suárez7Juan Miguel Rodríguez8Claudio Alba9María Luisa Montes10Rosa Martín-Mateos11Diego Burgos-Santamaría12Santiago Moreno13Santiago Moreno14Sergio Serrano-Villar15Sergio Serrano-Villar16Matilde Sánchez-Conde17Matilde Sánchez-Conde18Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainUniversidad Complutense de Madrid (UCM), Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainDepartment of Nutrition and Food Science, Complutense University of Madrid, Madrid, SpainDepartment of Nutrition and Food Science, Complutense University of Madrid, Madrid, SpainHIV Unit - Internal Medicine Service, Hospital Universitario La Paz, Madrid, SpainDepartment of Gastroenterology and Hepatology, Metabolic Liver Disease Clinic, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainDepartment of Gastroenterology and Hepatology, Metabolic Liver Disease Clinic, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainDepartment of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, SpainIntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH). The gut-liver axis is considered to be strongly implicated in the pathogenesis of MASLD. We aimed to characterize the gut microbiota composition in PLWH and MASLD and compare it with that of two control groups: PLWH without MASLD and individuals with MASLD without HIV infection.MethodsWe collected clinical data and stool samples from participants. Bacterial 16S rRNA genes were amplified, sequenced, and clustered into operational taxonomic unit. Alpha diversity was studied by Shannon and Simpson indexes. To study how different the gut microbiota composition is between the different groups, beta diversity estimation was evaluated by principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity. To further analyze differences in microbiome composition we performed a linear discriminant analysis (LDA) effect size (LEfSe).ResultsWe included 30 HIV+MASLD+, 30 HIV+MASLD- and 20 HIV-MASLD+ participants. Major butyrate producers, including Faecalibacterium, Ruminococcus, and Lachnospira dominated the microbiota in all three groups. Shannon’s and Simpson’s diversity metrics were higher among MASLD+ individuals (Kruskal-Wallis p = 0.047). Beta diversity analysis showed distinct clustering in MASLD-, with MASLD+ participants overlapping regardless of HIV status (ADONIS significance <0.001). MASLD was associated with increased homogeneity across individuals, in contrast to that observed in the HIV+NAFDL- group, in which the dispersion was higher (Permanova test, p value <0.001; ANOSIM, p value <0.001). MASLD but not HIV determined a different microbiota structure (HIV+MASLD- vs. HIV+MASLD+, q-value = 0.002; HIV-MASLD+ vs. HIV+MASLD+, q-value = 0.930; and HIV-MASLD+ vs. HIV+MASLD-, q-value < 0.001). The most abundant genera in MASLD- were Prevotella, Bacteroides, Dialister, Acidaminococcos, Alloprevotella, and Catenibacterium. In contrast, the most enriched genera in MASLD+ were Ruminococcus, Streptococcus, Holdemanella, Blautia, and Lactobacillus.ConclusionsWe found a microbiome signature linked to MASLD, which had a greater influence on the overall structure of the gut microbiota than HIV status alone.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1297378/fullHIVMASLDNAFLDgut microbiomemicrobiome |
| spellingShingle | Javier Martínez-Sanz Javier Martínez-Sanz Alba Talavera-Rodríguez Alba Talavera-Rodríguez Alba Talavera-Rodríguez Jorge Díaz-Álvarez Marta Rosas Cancio-Suárez Marta Rosas Cancio-Suárez Juan Miguel Rodríguez Claudio Alba María Luisa Montes Rosa Martín-Mateos Diego Burgos-Santamaría Santiago Moreno Santiago Moreno Sergio Serrano-Villar Sergio Serrano-Villar Matilde Sánchez-Conde Matilde Sánchez-Conde A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease Frontiers in Immunology HIV MASLD NAFLD gut microbiome microbiome |
| title | A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease |
| title_full | A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease |
| title_fullStr | A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease |
| title_full_unstemmed | A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease |
| title_short | A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease |
| title_sort | gut microbiome signature for hiv and metabolic dysfunction associated steatotic liver disease |
| topic | HIV MASLD NAFLD gut microbiome microbiome |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1297378/full |
| work_keys_str_mv | AT javiermartinezsanz agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT javiermartinezsanz agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT jorgediazalvarez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT martarosascanciosuarez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT martarosascanciosuarez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT juanmiguelrodriguez agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT claudioalba agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT marialuisamontes agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT rosamartinmateos agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT diegoburgossantamaria agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT santiagomoreno agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT santiagomoreno agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT sergioserranovillar agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT sergioserranovillar agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT matildesanchezconde agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT matildesanchezconde agutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT javiermartinezsanz gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT javiermartinezsanz gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT albatalaverarodriguez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT jorgediazalvarez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT martarosascanciosuarez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT martarosascanciosuarez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT juanmiguelrodriguez gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT claudioalba gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT marialuisamontes gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT rosamartinmateos gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT diegoburgossantamaria gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT santiagomoreno gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT santiagomoreno gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT sergioserranovillar gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT sergioserranovillar gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT matildesanchezconde gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease AT matildesanchezconde gutmicrobiomesignatureforhivandmetabolicdysfunctionassociatedsteatoticliverdisease |